Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 5 30 versus LO MINASTRIN FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 5 30 versus LO MINASTRIN FE.
LARIN 1.5/30 vs LO MINASTRIN FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
None Documented
None Documented
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive